• Takehiro Takahashi, Yoshihide Asano, Kaname Akamata, Naohiko Aozasa, Takashi Taniguchi, Shinji Noda, Yuri Masui, Yohei Ichimura, Tetsuo Toyama, Zenshiro Tamaki, Yayoi Tada, Makoto Sugaya, Takafumi Kadono, and Shinichi Sato.
• Department of Dermatology, Faculty of Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
• Mod Rheumatol. 2013 Sep 1;23(5):884-90.

ObjectiveAngiopoietin-2 (Ang2) regulates the transition between vascular quiescence and angiogenesis in a context-dependent manner. In systemic sclerosis (SSc), serum Ang2 levels correlate with its disease activity. Therefore, we investigated the clinical significance of monitoring serum Ang2 levels during intravenous pulse cyclophosphamide (IVCY) therapy in SSc patients with interstitial lung disease (ILD).MethodsSerum Ang2 levels were determined by a specific enzyme-linked immunosorbent assay in seven SSc patients treated with IVCY and 20 healthy controls. In the patient group, serum samples were drawn the day before each IVCY therapy.ResultsSerum Ang2 levels tended to be higher in SSc patients before IVCY than in healthy controls and significantly correlated with KL-6, surfactant protein D, erythrocyte sedimentation rate, and C-reactive protein in SSc patients with ILD. In sera drawn before the last IVCY, Ang2 levels were significantly decreased compared with initial levels. Notably, Δ serum Ang2 levels between baseline and after the first IVCY significantly correlated with Δ ILD score between before and after the entire IVCY therapy (r = 0.90, p < 0.01).ConclusionMonitoring Ang2 levels during IVCY treatment may be useful to evaluate and predict the efficacy of this treatment for SSc-ILD.

24 keywords...

hide…